1
Gerald B Grindey, Larry W Hertel: Method of treating tumors in mammals with 2,2-difluoronucleosides. Eli Lilly and Company, Robert A Conrad, November 7, 1995: US05464826 (84 worldwide citation)

A method of treating susceptible neoplasms in mammals comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound of the formula ##STR1## wherein: R.sup.1 is hydrogen;


2
Douglas P Kjell: Catalytic stereoselective glycosylation process for preparing 2-deoxy-2,2-difluoronucleosides and 2-deoxy-2-fluoronucleosides. Eli Lilly and Company, Robert A Conrad, David E Boone, June 20, 1995: US05426183 (83 worldwide citation)

A catalytic stereoselective glycosylation process for preparing beta- and alpha-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides involving reacting an alpha- or beta- anomer enriched 2-deoxy-2,2-difluorocarbohydrate or 2-deoxy-2-fluorocarbohydrate with at least a ...


3
David W Robertson, David T Wong, Joseph H Krushinski Jr: 3-aryloxy-3-substituted propanamines. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, June 11, 1991: US05023269 (65 worldwide citation)

The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.


4
Edward E Beedle, David W Robertson, David T Wong: Serotonin antagonists. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, May 7, 1991: US05013761 (60 worldwide citation)

This invention provides a method of selectively antagonizing the 5-HT.sub.1A receptor in mammals by administering aryloxypropanolamines. Novel aryloxypropanolamines are also claimed.


5
F P Carr, Robert D Dillard, Doris E McCullough: Leukotriene antagonists and use thereas. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, August 1, 1989: US04853398 (58 worldwide citation)

This invention provides benzene derivatives which are leukotriene antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.


6
David W Robertson, David T Wong, Joseph H Krushinski Jr: 3-aryloxy-3-substituted propanamines. Eli Lilly and Company, Robert A Conrad, September 11, 1990: US04956388 (56 worldwide citation)

The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.


7
Marvin E Wildfeuer: 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides. Eli Lilly and Company, Margaret M Brumm, Robert A Conrad, David E Boone, May 28, 1996: US05521294 (49 worldwide citation)

This invention provides novel 1-alkylsulfonyl-2,2-difluoro-3-carbamoyl ribose intermediates and intermediate nucleosides derived therefrom. The compounds are particularly useful in the preparation of 2'-deoxy-2',2'-difluoro-beta-cytidine and other beta anomer nucleosides which are antiviral and anti ...


8
Ta Sen Chou: Stereoselective fusion glycosylation process for preparing 2-deoxy-2,2-difluoronucleosides and 2-deoxy-2-fluoronucleosides. Eli Lilly and Company, Sidney Persley, Robert A Conrad, David E Boone, March 28, 1995: US05401838 (48 worldwide citation)

A stereoselective fusion glycosylation process for prearing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleotides and 2'-deoxy-2'-fluoronucleosides by reacting an alpha-anomer enriched 2-deoxy-2,2-difluorocarbohydrate or 2-deoxy-2-fluorcarbohydrate with at least a 3 molar equivalent of a nucleobas ...


9
Paul L Ornstein: Excitatory amino acid receptor antagonists. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, February 20, 1990: US04902695 (40 worldwide citation)

The present invention provides novel bicyclic derivatives useful as excitatory amino acid receptor antagonists and in treating a variety of associated nervous system disorders.


10
Sherryl L Lifer, Winston S Marshall, Fariborz Mohamadi, Jon K Reel, Richard L Simon, Mitchell I Steinberg, Celia A Whitesitt: Angiotensin II antagonist 1,3-imidazoles and use thereas. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, December 17, 1991: US05073566 (39 worldwide citation)

This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.